Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIOH-1: pritelivir versus foscarnet for acyclovir-resistant mucocutaneous HSV infection in immunocompromised patients
CTR20221218Phase 3Active
- Sponsor
- AiCuris
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pritelivir, foscarnet sodium in herpes simplex (HSV), mucocutaneous herpes simplex virus infection (HSV), sponsored by AiCuris. Started May 2022; status: active.
02
Drugs
pritelivirfoscarnet sodium
03
Conditions
herpes simplex (HSV)mucocutaneous herpes simplex virus infection (HSV)
Beyond the preview
Go deeper on CTR20221218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221218.